2000
DOI: 10.1006/bbrc.2000.2414
|View full text |Cite
|
Sign up to set email alerts
|

The Carboxyl Terminal Domain of Phosducin Functions as a Transcriptional Activator

Abstract: In previous work, we identified a set of phosducin (Phd) isoforms with unknown function including the phosducin (Phd)-like orphan protein 1 (PhLOP1), an amino terminal truncated isoform of the retinal Phd lacking the Gbetagamma binding domain. To investigate the potential biological function of PhLOP1, PhLOP1 was fused at its amino terminus with the DNA binding domain (BD) of the yeast transcriptional factor, GAL4, and used as bait in a yeast two-hybrid screen. Two potential functional protein partners were id… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
12
0

Year Published

2000
2000
2010
2010

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 41 publications
(26 reference statements)
1
12
0
Order By: Relevance
“…Another hypothesis, also consistent with the reduction of ␤␥ subunits in the rods of phosducin knockout mice, is that phosducin participates in transcriptional regulation (42). This hypothesis is based on the observations that 1) the phosducin C-terminal domain of 40 amino acid residues could serve as a transcriptional activator in both yeast and mammalian cells (42), 2) phosducin interacts with the photoreceptor-specific transcription factor CRX in vitro (43), and 3) a fraction of phosducin is present in the nuclei of bovine rods (27).…”
Section: Discussionsupporting
confidence: 54%
See 1 more Smart Citation
“…Another hypothesis, also consistent with the reduction of ␤␥ subunits in the rods of phosducin knockout mice, is that phosducin participates in transcriptional regulation (42). This hypothesis is based on the observations that 1) the phosducin C-terminal domain of 40 amino acid residues could serve as a transcriptional activator in both yeast and mammalian cells (42), 2) phosducin interacts with the photoreceptor-specific transcription factor CRX in vitro (43), and 3) a fraction of phosducin is present in the nuclei of bovine rods (27).…”
Section: Discussionsupporting
confidence: 54%
“…This hypothesis is based on the observations that 1) the phosducin C-terminal domain of 40 amino acid residues could serve as a transcriptional activator in both yeast and mammalian cells (42), 2) phosducin interacts with the photoreceptor-specific transcription factor CRX in vitro (43), and 3) a fraction of phosducin is present in the nuclei of bovine rods (27). In the next study using the phosducin knockout mouse we plan to analyze the reduction in transducin ␤␥ subunits in the context of either its reduced synthesis or its enhanced proteolysis.…”
Section: Discussionmentioning
confidence: 99%
“…In all amniotes except primates, phosducin has three exons; the last begins in the same place in all amniotes. Our primers match the cAMP-dependent protein kinase (PKA) recognition site at the 5 0 end (Kobayashi et al, 2002), and a conserved region thought to be important for transcriptional regulation at the 3 0 end (Zhu and Craft, 2000). Both the primer sites and the resulting phosducin sequences reported here are all part of the third exon.…”
Section: Dna Extraction Amplification and Sequencingmentioning
confidence: 94%
“…It is expressed in high levels in retinal photoreceptor and pineal cells (Lee et al, 2004). In addition to light-activated dephosphorylation in photoreceptor cells (Kobayashi et al, 2002;Lee et al, 2004), phosducin also has a role as a transcriptional activator (Zhu and Craft, 2000). For the known sequences in amniotes, the number of amino acids varies from 244 in Mus musculus to 249 in Phelsuma madagascariensis.…”
Section: Dna Extraction Amplification and Sequencingmentioning
confidence: 99%
“…Frameshift mutations of the C-terminal portion of CRX will lead to alteration of the encoded sequence and loss of the OTX tail, which may affect interactions with other factors, e.g. NRL, RX, p300/CBP, and phosducin (3,15,(21)(22)(23)(24).…”
mentioning
confidence: 99%